Relapsed Refractory Chronic Lymphocytic Leukemia Cll Or Small Lymphocytic Lymphoma Sll clinical trials

Explore recruiting relapsed refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll clinical trials.

Recruiting relapsed refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Chronic Lymphocytic Leukemia Cll Or Small Lymphocytic Lymphoma Sll trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A dose escalation followed by dose expansion trial to assess safety and tolerability of CAP-100 in subjects with relapsed/refractory chronic lymphocytic leukemia.

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Relapsed Refractory Chronic Lymphocytic Leukemia Cll Or Small Lymphocytic Lymphoma Sll trials by city

Relapsed Refractory Chronic Lymphocytic Leukemia Cll Or Small Lymphocytic Lymphoma Sll clinical trials

Recruiting relapsed refractory chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll studies right now

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Also recruiting in Europe

A dose escalation followed by dose expansion trial to assess safety and tolerability of CAP-100 in subjects with relapsed/refractory chronic lymphocytic leukemia.

Relapsed Refractory Chronic Lymphocytic Leukemia Cll Or Small Lymphocytic Lymphoma Sll trials by city

Other conditions